Allergy Point-of-Care Testing Market Report 2026

The allergy point-of-care testing market size has grown rapidly in recent years. It will grow from $1.33 billion in 2025 to $1.49 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rising prevalence of allergic disorders globally, increasing clinical awareness of early allergy diagnosis, expansion of immunoassay technologies in diagnostics, growth in hospital based laboratory testing infrastructure, increasing pediatric allergy cases.

The allergy point-of-care testing market size is expected to see rapid growth in the next few years. It will grow to $2.34 billion by 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to expansion of point of care diagnostic adoption, growth in personalized medicine approaches for allergy management, increasing demand for rapid home based testing solutions, integration of ai enabled diagnostic interpretation tools, rising healthcare decentralization and outpatient care expansion. Major trends in the forecast period include increasing adoption of rapid immunoglobulin e based allergy diagnostics, rising demand for portable point of care testing devices, expansion of decentralized allergy screening in primary care settings, growth in immunoassay based rapid allergy detection kits, increasing integration of digital health platforms in allergy testing workflows.

The growing prevalence of allergic conditions is anticipated to drive the expansion of the allergy point of care testing market forward. Allergic conditions are immune system disorders in which the body reacts excessively to harmless substances, resulting in symptoms such as sneezing, skin rashes, and breathing difficulties. The prevalence of allergic conditions is increasing due to greater exposure to environmental allergens, including pollen, dust, and pollution, which provoke immune system overreactions in susceptible individuals. Allergy point-of-care testing allows fast and convenient identification of specific allergens, enabling healthcare providers to quickly determine triggers, support tailored treatment strategies, and assist individuals in effectively managing and reducing the impact of allergic conditions. For instance, in November 2025, according to Asthma Australia, an Australia-based non-profit organization, 322 women died from asthma last year compared with 156 men, which is more than twice as many. This pattern has remained unchanged since 2023, with half of the 478 total deaths occurring in women aged 75 and over. Therefore, the growing prevalence of allergic conditions is contributing to the growth of the allergy point of care testing market.

Leading companies operating in the allergy point-of-care testing market are focusing on developing innovative products such as semi-quantitative point-of-care diagnostic devices to deliver rapid, accurate allergy test results in clinical settings. Semi-quantitative point-of-care diagnostic devices are tools that measure approximate levels of specific biomarkers, such as IgE, directly at the clinic, providing rapid, reliable results that enable healthcare providers to quickly assess the severity of allergic responses and make immediate, informed treatment decisions without waiting for traditional laboratory tests. For example, in June 2024, Kenota Health, a Canada-based medical technology company, received U. S. Food and Drug Administration (FDA) clearance and a CLIA waiver for the Kenota 1 Total IgE test system, enabling its use in point-of-care clinical settings. The Kenota 1 system is a semi-quantitative diagnostic device that measures total IgE levels from a minimal fingerstick blood sample, delivering results in under 30 minutes with automated operation, unlike traditional laboratory IgE tests that require venous blood draws and several days for results. The system is designed for rapid, in-office allergy assessment, offering features such as a small blood volume requirement of 4.5 microliters per test, easy-to-use operation, and the capacity to run 15-60 tests per session. Its applications include supporting the diagnosis of IgE-mediated allergic disorders and enabling clinicians to make immediate patient care decisions, streamlining allergy management and improving patient outcomes.

The increasing healthcare expenditure is anticipated to drive the expansion of the allergy point-of-care testing market forward. Healthcare expenditure refers to the total financial resources spent on health services, medical products, public health programs, and healthcare infrastructure by governments, private entities, and individuals. Healthcare expenditure is rising due to the growing demand for medical services, as more patients require consultations, treatments, and diagnostic procedures, which increases overall healthcare spending. Healthcare expenditure supports the growth of allergy point-of-care (POC) testing by enabling investment in advanced diagnostic technologies, promoting rapid testing at or near patient care settings, reducing dependence on centralized laboratories, and enhancing efficiency along with overall healthcare outcomes. For instance, in January 2026, according to the Centers for Medicare & Medicaid Services, a US-based government agency, in 2024, National Health Expenditure (NHE) rose by 7.2% to reach $5.3 trillion, averaging $15,474 per person, and accounted for 18% of the Gross Domestic Product (GDP). Therefore, the increasing healthcare expenditure is driving the growth of the allergy point-of-care testing market.

Major companies operating in the allergy point-of-care testing market are Siemens Healthineers AG, F. Hoffmann‑La Roche Ltd, Hitachi Chemical Diagnostic Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Eurofins Scientific SE, bioMérieux SA, Quidel Corporation, EUROIMMUN Medizinische Labordiagnostika AG, R-Biopharm AG, HOB Biotech Group Corp. Ltd., Hycor Biomedical Inc., Omega Diagnostics Ltd, Lincoln Diagnostics Inc., Alerchek Inc., Abionic SA, Kenota Health Inc.

North America was the dominating region in the allergy point-of-care testing market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the allergy point-of-care testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the allergy point-of-care testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allergy point-of-care testing market consists of revenues earned by entities by providing services such as allergy screening, rapid diagnostic testing, patient sample collection, immunoassay analysis, result interpretation, counseling and consultation, allergy monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The allergy point-of-care testing market also includes sales of point-of-care test kits, lancets, test strips, immunoassay devices, blood collection devices, skin prick test devices, lateral flow assay cassettes, analyzers, sample collection tubes, and diagnostic reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.